EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang iD, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai und 5 weitere

Advanced Science · 2026

DOI: 10.1002/advs.76352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jinchen Luo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, TOR Serine-Threonine Kinases, Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Guangzhou Basic Research Program-City-University (Hospital)-Enterprise Joint Funding Project, Guangxi Natural Science Foundation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.

Methods

Integrated RNA sequencing of cabozantinib‐resistant RCC cells, lipid metabolomics, and PD‐L1 correlation analyses identified ENPP2 as a candidate driver. Its role in TKI resistance and survival signaling was validated by apoptosis, CCK‐8, and colony formation assays in vitro and by nude‐mouse xenograft models in vivo. ELISA, flow cytometry and tumor cell–T‐cell co‐culture assays were used to dissect ENPP2‐dependent CD8+ T‐cell dysfunction. The therapeutic benefit of pharmacologic ATX inhibition combined with standard TKI–ICI regimens was tested in RCC patient‐derived xenograft models.

Results

The ATX–LPA axis conferred TKI resistance via constitutive AKT/mTOR activation and promoted immune evasion by upregulating PD‐L1 through TBK1/IRF3 signaling, thereby impairing intratumoral CD8+ T‐cell function. ENPP2 enhanced PD‐L1 transcription by facilitating IRF3 nuclear translocation and its direct recruitment to the CD274 promoter. ATX inhibition improved the antitumor efficacy of TKI–ICI therapy in preclinical models.

Conclusions

Targeting the ATX–LPA axis represents a promising strategy to overcome resistance to current TKI–ICI combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellTOR Serine-Threonine KinasesProtein Serine-Threonine KinasesDrug Resistance, NeoplasmProto-Oncogene Proteins c-aktKidney NeoplasmsProtein Kinase InhibitorsInterferon Regulatory Factor-3Phosphoric Diester HydrolasesHumansAnimalsMiceSignal TransductionLysophospholipase DMice, NudeCell Line, TumorTyrosine Kinase InhibitorsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ENPP2/ATXRenal cell carcinoma (RCC)Tyrosine kinase inhibitorimmunotherapy

Substanzen

TOR Serine-Threonine KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktProtein Kinase InhibitorsMTOR protein, humanTBK1 protein, humanInterferon Regulatory Factor-3Lysophospholipase DPhosphoric Diester HydrolasesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Urology Department, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Huadu District People's Hospital of Guangzhou, Guangzhou, China.
  • Huadu Institute of Medical Sciences, Guangzhou, China.
  • Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University, Nanning, China.
  • Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Yong Huang, Wei Chen, Junhang Luo, Yanping Liang

Förderung

  • Natural Science Foundation of China
  • Guangzhou Basic Research Program-City-University (Hospital)-Enterprise Joint Funding Project
  • Guangxi Natural Science Foundation Program
  • National Natural Science Foundation of China

Zitieren

APA

Luo, J., Lin, H., Feng, H., Tan, L., Liu, X., Huang, Y., Cen, J., Chen, J., Zhou, X., Lin, M., Liao, W., Ai, Z., Chen, M., Wang, Y., Chen, W., Luo, J., & Liang, Y. (2026). Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways. Advanced Science. https://doi.org/10.1002/advs.76352

Vancouver

Luo J, Lin H, Feng H, Tan L, Liu X, Huang Y, et al. Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways. Advanced Science. 2026. doi:10.1002/advs.76352

BibTeX
@article{Luo2026,
  author = {Luo, Jinchen and Lin, Hansen and Feng, Haoqian and Tan, Lei and Liu, Xi and Huang, Yong and Cen, Junjie and Chen, Jiajie and Zhou, Xinwei and Lin, Mingjie and Liao, Wuyuan and Ai, Zheyu and Chen, Minyu and Wang, Yinghan and Chen, Wei and Luo, Junhang and Liang, Yanping},
  title = {Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76352}
}
Kostenlos starten →